German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis

Trial Profile

German-Austrian Register to Evaluate the Short and Long-term Safety and Therapy Outcomes of the ABSORB Everolimus-eluting Bioresorbable Vascular Scaffold System in Patients With Coronary Artery Stenosis

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 29 Jun 2017

At a glance

  • Drugs Everolimus (Primary)
  • Indications Coronary artery disease; Coronary artery restenosis
  • Focus Adverse reactions
  • Acronyms GABI-R
  • Most Recent Events

    • 26 Jun 2017 Status changed from active, no longer recruiting to recruiting.
    • 23 Feb 2016 Planned End Date changed from 1 Apr 2020 to 1 Mar 2021, according to ClinicalTrials.gov record.
    • 23 Feb 2016 Planned primary completion date changed from 1 Apr 2020 to 1 Mar 2021, according to ClinicalTrials.gov record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top